Product Information
LEVONOR-ETH ESTRAD 0.15-0.03 is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.1128 per EA under NDC 00378655053. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Dec 21, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378655053
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA091663FDA Approved
12/21/2012
TE Code
AB
On Market Since
8/16/2013
Price Statistics
The NADAC for LEVONOR-ETH ESTRAD 0.15-0.03 has been published 665 times since Nov 28, 2013, and over the history we have for it it has declined 82.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1128 per EA |
|---|---|
| All-time high | $0.6294 (Dec 11, 2013) |
| All-time low | $0.0800 (Nov 20, 2024) |
| 52-week high | $0.1210 |
| 52-week low | $0.1090 |
| Median price | $0.2325 |
| Average price | $0.2846 |
| Largest weekly change | +72.0% (Aug 21, 2024) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
+0.2%
6M
+0.4%
1Y
-1.2%
3Y
-25.3%
5Y
-41.9%
All
-82.1%
Last surveyed Aug 19, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levonorgestrel and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVONOR-ETH ESTRAD 0.15-0.03?
The current National Average Drug Acquisition Cost (NADAC) for LEVONOR-ETH ESTRAD 0.15-0.03, manufactured by Mylan Pharmaceuticals Inc., is $0.1128 per EA (NDC 00378655053), effective Aug 19, 2026.
How has the price of LEVONOR-ETH ESTRAD 0.15-0.03 changed over time?
Over the history we have for it, the NADAC for LEVONOR-ETH ESTRAD 0.15-0.03 has declined 82.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LEVONOR-ETH ESTRAD 0.15-0.03?
Since Nov 28, 2013, the NADAC for LEVONOR-ETH ESTRAD 0.15-0.03 has ranged from a low of $0.0800 (Nov 20, 2024) to a high of $0.6294 (Dec 11, 2013), with a median of $0.2325 per EA.
Are there cheaper alternatives to LEVONOR-ETH ESTRAD 0.15-0.03?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LEVONOR-ETH ESTRAD 0.15-0.03 in a comparable dosage form, but none are currently priced below it.
Who manufactures LEVONOR-ETH ESTRAD 0.15-0.03?
LEVONOR-ETH ESTRAD 0.15-0.03 (NDC 00378655053) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.